Clinical Trials List
2018-06-01 - 2020-05-31
Phase I
Terminated5
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.09
Secondary carcinoid tumors of other sites
ICD-10C7B.1
Secondary Merkel cell carcinoma
ICD-10C7B.8
Other secondary neuroendocrine tumors
ICD-10C80.0
Disseminated malignant neoplasm, unspecified
ICD-10D3A.8
Other benign neuroendocrine tumors
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.0
Disseminated malignant neoplasm
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Chao-Hua Chiu Division of Hematology & Oncology
- Rheun-Chuan Lee Division of Radiology
- Yu-Chung Wu Division of Hematology & Oncology
- Chung-Pin Li Digestive System Department
- 盧星華 Division of Obstetrics & Gynecology
- Ming-Huang Chen Division of Hematology & Oncology
- Chun-Yu Liu Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
- Ta-Chung Chao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- CHIA-CHUN KUO Division of Radiation Therapy
- MING-CHE LIU Division of Urology
- Huey-En Tzeng Division of Hematology & Oncology
- Wei-Yu Kao Digestive System Department
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Jih-Hsiang Lee Division of Hematology & Oncology
- 許嘉林 Division of General Internal Medicine
- 蔡子修 Division of General Internal Medicine
- CHAO-CHI HO CHAO-CHI HO Division of General Internal Medicine
- 陳冠宇 Division of General Internal Medicine
- 廖唯昱 Division of General Internal Medicine
- James Chih-Hsin Yang Division of Hematology & Oncology
- 楊景堯 Division of General Internal Medicine
- Wen-Fang Cheng Division of Obstetrics & Gynecology
- JHE-CYUAN GUO Division of Hematology & Oncology
- YEN-SHEN LU Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- Yu-Chieh Tsai Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
- 林季宏 Division of Hematology & Oncology
- 廖斌志 Division of Hematology & Oncology
- 吳尚俊 Division of General Internal Medicine
- JIN-YUAN SHIH Division of General Internal Medicine
- Chong-Jen Yu Division of General Internal Medicine
- Kun-Huei Yeh Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 周宏學 Division of Obstetrics & Gynecology
- Jen-Shi Chen Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- 邱健泰 Division of Obstetrics & Gynecology
- Yung-Chang Lin Division of Hematology & Oncology
- Wen-Cheng Chang Division of Hematology & Oncology
- 黃振洋 Division of Hematology & Oncology
- Wen-Chi Shen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wu-Chou Su Division of Hematology & Oncology
- Yu-Min Yeh Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
- 劉亦廷 Division of Hematology & Oncology
- Wen-Pin Su Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
6 & 30 participants
-
Global
20 & 100 participants
